Perampanel as add-on therapy in epilepsies with known etiology: A single center experience with long-term follow-up.

Autor:	Nilo A; Department of Medicine (DAME), University of Udine Medical School, Udine, Italy.; Clinical Neurology Unit, Department of Neurosciences, S. Maria della Misericordia University Hospital, Udine, Italy., Pauletto G; Neurology Unit, Department of Neurosciences, S. Maria della Misericordia University Hospital, Udine, Italy., Gigli GL; Department of Medicine (DAME), University of Udine Medical School, Udine, Italy.; Clinical Neurology Unit, Department of Neurosciences, S. Maria della Misericordia University Hospital, Udine, Italy.; DMIF, University of Udine, Udine, Italy., Vogrig A; Clinical Neurology Unit, Department of Neurosciences, S. Maria della Misericordia University Hospital, Udine, Italy., Dolso P; Clinical Neurology Unit, Department of Neurosciences, S. Maria della Misericordia University Hospital, Udine, Italy., Valente M; Department of Medicine (DAME), University of Udine Medical School, Udine, Italy.; Clinical Neurology Unit, Department of Neurosciences, S. Maria della Misericordia University Hospital, Udine, Italy.
Jazyk:	angličtina
Zdroj:	Epilepsy & behavior reports [Epilepsy Behav Rep] 2020 Oct 26; Vol. 15, pp. 100393. Date of Electronic Publication: 2020 Oct 26 (Print Publication: 2021).
DOI:	10.1016/j.ebr.2020.100393
Abstrakt:	We report a retrospective monocentric study performed on 63 patients affected by epilepsy with known etiology, receiving perampanel as add-on therapy with at least 12-month follow-up. The purpose of our study was to evaluate efficacy and tolerability of perampanel in this group of epilepsies. Patients were classified into 2 groups based on the presence/absence of a single focal brain lesion on MRI, as epilepsy etiology: 48 subjects were affected by focal lesional epilepsy and 15 by non-focal lesional epilepsy. The retention rate was 76.2% and 53.9% at 12 and 24 months respectively. At 12 months, at least 40% of patients resulted responders, with a significant reduction in seizure frequency ( p  = 0.01), confirmed at 24 months. Considering epilepsy etiology, we found a better PER response in patients with focal lesional epilepsy. A significant correlation was observed between responder rates and EEG pattern. Only 30% of patients reported mild-moderate adverse events. Efficacy and tolerability of PER, in our study, are in line with the results reported in other real-world studies. Our data suggest the possibility of better PER response in patients with focal brain lesions, which indicates that this drug could be a therapeutic option in this population. (© 2020 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu